Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III anifrolumab study in chronic or subacute cutaneous lupus erythematosus
NL-OMON60633Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of anifrolumab in cutaneous lupus erythematosus (CLE), sponsored by AstraZeneca. Started Nov 2024; status: active, not recruiting.
02
Drugs
anifrolumab
03
Conditions
cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NL-OMON60633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60633.